As a Clinical Laboratory Improvements Amendments (CLIA) certified lab, Genelex strives to adhere to best practices and deliver accurate and comprehensive results. Our results are backed by clinical validity, analysis, and ongoing support to our customers.
We leverage a powerful combination of innovative analytics software, state-of-the-art laboratory facilities, and expert staff, to perform high-quality testing and medication management. As a flagship product, Genelex offers MedMPact, a PGx test that analyzes medication metabolic impact based on a patient’s genes and the medications they take.
More than 90% of the US population has at least one genetic variation that may affect their response to medications.
Genelex is the only genetics lab to offer a clinical decision support tool (CDST) for providers in conjunction with genetic testing.
Currently, more than 250 medications have PGx information and/or FDA warnings printed on their labels. 
FOR CLINICIAL TRIALS:
Genelex offers an unrivaled depth of experience to pharmaceutical companies and other research organizations.
What Patients Are Saying About Genelex:
"I used to suffer from horrific side effects as bad as the condition being treated. Pharmacogenetic testing has changed that. I am very grateful for Genelex!"
Andrew W. | King of Prussia, PA
"My physician switched my medications based on my test results, and I cannot describe how much better I feel. You have made a believer out of me, my family, and my physician."
Patricia Y. | Eirie, CO
"I have been having drug reactions for years and my doctors told me it was in my head. Now I have proof that I’m a poor metabolizer for many medications. I just wish I’d known about your test years ago."
Michael D. | Syracuse, NY
"Genelex was key in my physical and mental health by giving me objective, reliable data about my body’s ability to break down drugs. I refer people to Genelex often and know from personal experience the extreme value it had on my health."
Patricia M. | Seattle, WA
The Future of Personalized Medicine is Here
With over 30 years of experience in genetic testing, Genelex has the knowledge and expertise to bring you truly personalized medicine.
When it comes to prescribing drugs and evaluating patients for potential drug interactions, PGx testing is no longer a future consideration.
- The American Medical Association advocates that physicians become familiar with genetic variations that may affect patients’ drug metabolism and be able to recognize when testing should be used to inform prescribing.
- The U.S. Food and Drug Administration, the European Medicines Agency, and Health Canada currently require or recommend testing for more than 60 drugs.
- A report from the U.S. Department of Health and Human Services states: “Pharmacogenetic testing for potential ADEs and ineffective drug responses may reduce health care costs over the long term by diminishing the duration and severity of illness and the costs associated with ineffective treatment and avoidable ADEs.”
Each year in the United States, more than 2.2 million ADEs occur, resulting in more than 100,000 deaths and placing an enormous financial burden on the healthcare system.  Genelex has been a trailblazer in the area of genetic testing – focused, innovative, and driven to prevent ADEs.
At our fingertips, we have access to the tools essential for precision prescribing — allowing for personalizing medication decisions whenever they are made.
Genelex and Personalized Medicine
Genelex tests cytochromes (CYPs) and other genes, which are responsible for metabolizing most commonly prescribed medications.
While PGx is an important factor in drug metabolism, other factors such as age, lifestyle (e.g. smoking, alcohol consumption) and end-organ function (e.g. liver and kidney function) also play a role.
We provide pharmacist-produced reports that gives information on how to optimize medications, and providers get access to analytics software and a Clinical Decision Support Tool (CDST) to assist in determining medication options for each individual.
Once tested, each patient is classified as a: Poor Metabolizer, Intermediate Metabolizer, Normal Metabolizer, Rapid Metabolizer, or Ultra-rapid Metabolizer. These classifications describe a patient’s inherent drug metabolizing capacity.
MedMPact combined with the CDST reveals drug-metabolizing gene variants—found in more than 90% of patients—to help healthcare providers and pharmacists.
Our reports include patient-specific information on potential drug-drug, drug-gene, and cumulative interactions mediated by the tested polymorphic drug metabolizing enzymes. The generated reports may inform providers with immediate insight into individual differences in their patients’ drug processing ability.
Have you ever wondered why a medication works extremely well for some but may have side effects for others?
PGx testing, through MedMPact, may answer this question and many others. We all have unique, complex genetic characteristics. We typically think of these characteristics as what determines our eye color or hair color. Genetics may play a role in how we respond to medications.
Due to of these genetic differences, two people can take the same dose of the same drug but may respond in very different ways. For example, the drug might work very well for one person, but not at all for another. Or the drug might cause side effects for one person, but not for someone else.
In some cases, drug-related side effects may be serious or cause death – even though the drug was prescribed normally by the doctor and used correctly by the patient. People who take several different drugs face an even greater risk of dangerous side effects, especially if they are over 65 years of age.